[Treatment of allergic rhinitis in the biologics era].

Authors

Yuan Zhang, Chengshuo Wang, Luo Zhang

Published in

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery. Volume 40. Issue 7. Pages 603-607.

Abstract

Objective:Allergic rhinitis（AR） is a major chronic disease that severely affects human health. The primary objective of current treatment modalities is symptom relief, yet patients often exhibit poor adherence to long-term therapy with suboptimal efficacy outcomes. Since the 1990 s, monoclonal antibodies targeting key cytokines and their receptors in type 2 inflammatory responses have been employed to treat type 2 inflammatory diseases such as AR. Clinical studies have demonstrated that omalizumab, dupilumab, and stapokibart are effective in treating seasonal AR. In 2025, stapokibart was approved for the treatment of moderate-to-severe seasonal AR in adults, becoming the world's first targeted IL-4Rα monoclonal antibody for AR therapy. This article systematically reviews the history and efficacy of biologics in the treatment of AR, as well as the development of domestic biologics, aiming to emphasize the importance of their clinical application strategies.

PMID:
42402677
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.